Efficacy of 18F-FDG and 18F-FLT PET/CT for Assessment of Chemoradiotherapy in Patient with Non-Small Cell Lung Cancer (Clinical Observation)
https://doi.org/10.24835/1607-0763-2017-1-53-56
Abstract
PET/CT offers the most advanced possibilities for visualization of non-small cell lung cancer (NSCLC) nowadays. 18F-FDG PET/CT plays a significant role in staging of NSCLC, choosing of treatment strategy, planning of radiation therapy and evaluation of its efficacy. Clinical observation of the patient with non-small cell lung cancer with response assessments by 18F-FDG and 18FFLT PET/CT during the course of chemoirradiation is demonstrated. There was a correlation between 18F-FDG and 18F-FLT PET/CT with advantage of 18F-FLT PET/CT for early response evaluation. The combination of 18F-FDG and 18FFLT PET/CT will be helpful to personalize chemoirradiation and to predict response more accurately. The presented clinical case demonstrated the possibilities of 18F-FDG and 18F-FLT PET/CT for assessment of treatment efficacy in patient with non-small cell lung cancer.
About the Authors
N. A. Meshcheryakova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Radiologist of PET/CT department of N.N. Blokhin RCRC, Moscow
115478, Moscow, Kashirskoe shosse, 23. Department of positron emission tomography of N.N. Blokhin RCRC. Phone: +7-925-884-22-23
M. B. Dolgushin
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
doct. of med. sci., Head of PET/CT Department of N.N. Blokhin RCRC, Moscow
T. N. Borisova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
cand. of med. sci., Senior Research Fellow of Radiology Department of N.N. Blokhin RCRC, Moscow
M. M. Davydov
N.N. Blokhin Russian Cancer Research Center
Russian Federation
doct. of med. sci., Head of Thoraco-Abdominal Department of N.N. Blokhin RCRC, Moscow
Russian Federation
doct. of med. sci., Head of Thoraco-Abdominal Department of N.N. Blokhin RCRC, Moscow
K. K. Laktionov
N.N. Blokhin Russian Cancer Research Center
Russian Federation
doct. of med. sci., Head of Surgical Department №13 of N.N. Blokhin RCRC, Moscow
Russian Federation
doct. of med. sci., Head of Surgical Department №13 of N.N. Blokhin RCRC, Moscow
References
1. Lardinois D., Weder W., Hany T.F. et al. Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003; 348: 2500–2507.
2. MacManus M., Nestle U., Rosenzweig K.E. et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother. Oncol. 2009; 91: 85–94.
3. Van Elmpt W., De Ruysscher D., van der Salm A. et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother. Oncol. 2012; 104 (1): 67–71.
4. Mac Manus M., Hicks R.J., Matthews J. et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005; 49: 95–108.
5. Van Baardwijk A., Bosmans G., Dekker A. et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy: a prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother. Oncol. 2007; 82:145–152.
6. Vera P., Bohn P., Edet-Sanson A. et al. Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F- fluoro-thymidine (FLT), and hypoxia with 18fluoro-miso- nidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother. Oncol. 2011; 98: 109–116.
7. Kenny L.M., Aboagye E.O., Price P.M. Positron emission tomography imaging of cell proliferation in oncology. Clin. Oncol. (R. Coll. Radiol.). 2004; 16: 176–185.
8. Everitt S.J., Ball D.L. Hicks R.J. et al. Differential 18F-FDG and 18F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. J. Nucl. Med. 2014; 55: 1069–1074.
9. Barwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl. Med. Commun. 2009; 30: 908–917.
10. Buck A.K., Herrmann K., Shen C. et al. Molecular imaging of proliferation in vivo: positron emission tomography with [18F] fluorothymidine. Methods. 2009; 48: 205–215.
11. Wahl R.L., Jacene H., Kasamon Y. et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (1): 122S–150S.
12. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009; 45 (2): 228–247.
Review
For citations:
Meshcheryakova N.A., Dolgushin M.B., Borisova T.N., Davydov M.M., Laktionov K.K. Efficacy of 18F-FDG and 18F-FLT PET/CT for Assessment of Chemoradiotherapy in Patient with Non-Small Cell Lung Cancer (Clinical Observation). Medical Visualization. 2017;(1):53-56. (In Russ.) https://doi.org/10.24835/1607-0763-2017-1-53-56
Views:
1490
Email this article 